Citrate as an in vivo marker to discriminate prostate cancer from benign prostatic hyperplasia and normal prostate peripheral zone: Detection via localized proton spectroscopy
- 31 March 1995
- journal article
- clinical trial
- Published by Elsevier BV in Urology
- Vol. 45 (3), 459-466
- https://doi.org/10.1016/s0090-4295(99)80016-8
Abstract
No abstract availableKeywords
This publication has 22 references indexed in Scilit:
- Characterization of Human Prostate Cancer, Benign Prostatic Hyperplasia and Normal Prostate by in vitro1H and31P Magnetic Resonance SpectroscopyJournal of Urology, 1993
- Current role of MR imaging in the staging of adenocarcinoma of the prostate.Radiology, 1993
- In vitro high resolution 1h‐spectroscopy of the human prostate: Benign prostatic hyperplasia, normal peripheral zone and adenocarcinomaMagnetic Resonance in Medicine, 1993
- Citrate alterations in primary and metastatic human prostatic adenocarcinomas: 1H magnetic resonance spectroscopy and biochemical studyMagnetic Resonance in Medicine, 1993
- The association of benign prostatic hyperplasia and cancer of the prostateCancer, 1992
- Differentiation of human prostate cancer from benign hypertrophy byin vitro1H NMRMagnetic Resonance in Medicine, 1992
- In Vitro proton spectroscopy of normal and abnormal prostateMagnetic Resonance in Medicine, 1991
- Prostatic carcinoma and benign prostatic hyperplasia: MR imaging with histopathologic correlation.Radiology, 1989
- Prostatic carcinoma and benign prostatic hyperplasia: correlation of high-resolution MR and histopathologic findings.Radiology, 1989
- Prostatic carcinoma and benign prostatic hyperplasia: inability of MR imaging to distinguish between the two diseases.Radiology, 1986